A novel ALK/EGFR (anaplastic lymphoma kinase/epidermal growth factor receptor) inhibitor—AP26113 (ARIAD Pharmaceuticals, Inc.)—achieved good responses in crizotinib-resistant and crizotinib-naive patients with non-small cell lung cancer (NSCLC) as well as radiographic regression of central nervous system (CNS) metastases in these patients. Read More ›
